Literature DB >> 26370679

Intrathecal Clonidine Pump Failure Causing Acute Withdrawal Syndrome With 'Stress-Induced' Cardiomyopathy.

Hwee Min D Lee1,2,3,4, Varuna Ruggoo5,6, Andis Graudins5,6,7.   

Abstract

Clonidine is a central alpha(2)-agonist antihypertensive used widely for opioid/alcohol withdrawal, attention deficit hyperactivity disorder and chronic pain management. We describe a case of clonidine withdrawal causing life-threatening hypertensive crisis and stress-induced cardiomyopathy. A 47-year-old man with chronic back pain, treated with clonidine for many years via intrathecal pump (550 mcg/24 h), presented following a collapse and complaining of sudden worsening of back pain, severe headache, diaphoresis, nausea and vomiting. A few hours prior to presentation, his subcutaneous pump malfunctioned. On presentation, vital signs included pulse 100 bpm, BP 176/103 mmHg, temperature 37.8 °C and O2 saturation 100 % (room air). Acute clonidine withdrawal with hypertensive crisis was suspected. Intravenous clonidine loading dose and a 50 mcg/h infusion were commenced. Five hours later, severe chest pain, dyspnoea, tachycardia, hypoxia, with BP 180/120 mmHg and pulmonary edema ensued. ECG showed sinus tachycardia with no ST elevation. Repeated intravenous clonidine doses were given (25 mcg every 5-10 min), with ongoing clonidine infusion to control blood pressure. Glyceryl trinitrate infusion, positive pressure ventilation and intravenous benzodiazepines were added. Bedside echocardiogram showed stress-induced cardiomyopathy pattern. Serum troponin-I was markedly elevated. His coronary angiography showed minor irregularities in the major vessels. Over the next 3 days in the ICU, drug infusions were weaned. Discharge was 12 days later on oral clonidine, metoprolol, perindopril, aspirin and oxycodone-SR. Two months later, his echocardiogram was normal. The intrathecal pump was removed. We report a case of stress-induced cardiomyopathy resulting from the sudden cessation of long-term intrathecal clonidine. This was managed by re-institution of clonidine and targeted organ-specific therapies.

Entities:  

Keywords:  Cardiomyopathy; Clonidine; Intrathecal; Sympathomimetic; Withdrawal

Mesh:

Substances:

Year:  2016        PMID: 26370679      PMCID: PMC4781811          DOI: 10.1007/s13181-015-0505-9

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  20 in total

1.  Myocardial infarction accompanying acute clonidine withdrawal in a patient without a history of ischemic coronary artery disease.

Authors:  K H Berge; W L Lanier
Journal:  Anesth Analg       Date:  1991-02       Impact factor: 5.108

Review 2.  Takotsubo cardiomyopathy: Pathophysiology, diagnosis and treatment.

Authors:  Kazuo Komamura; Miho Fukui; Toshihiro Iwasaku; Shinichi Hirotani; Tohru Masuyama
Journal:  World J Cardiol       Date:  2014-07-26

3.  Rebound hypertension and withdrawal associated with discontinuation of an infusion of epidural clonidine.

Authors:  D Fitzgibbon; S Rapp; S Butler; G Terman; G Dolack; S DuPen; L B Ready
Journal:  Anesthesiology       Date:  1996-03       Impact factor: 7.892

4.  Alpha receptors and ventricular tachycardia after clonidine withdrawal.

Authors:  S Nakagawa; Y Yamamoto; Y Koiwaya
Journal:  Br Heart J       Date:  1986-08

Review 5.  Alpha2 adrenergic agonists for the management of opioid withdrawal.

Authors:  L Gowing; M Farrell; R Ali; J White
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

6.  Evaluation of clonidine hydrochloride (Catapres). A new antihypertensive agent.

Authors:  M E Kosman
Journal:  JAMA       Date:  1975-07-14       Impact factor: 56.272

7.  Acute myocardial infarction as a complication of clonidine withdrawal.

Authors:  John Simic; Stephen Kishineff; Richard Goldberg; William Gifford
Journal:  J Emerg Med       Date:  2003-11       Impact factor: 1.484

8.  Rebound hypertension following abrupt cessation of clonidine and metoprolol. Treatment with labetalol.

Authors:  J L Mehta; L M Lopez
Journal:  Arch Intern Med       Date:  1987-02

9.  Changes in blood pressure, plasma catecholamines and plasma renin activity during and after treatment with tiamenidine and clonidine.

Authors:  B G Hansson; B Hökfelt
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335

10.  Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis.

Authors:  W Burleson Daviss; Nick C Patel; Adelaide S Robb; Michael P McDERMOTT; Oscar G Bukstein; William E Pelham; Donna Palumbo; Peter Harris; Floyd R Sallee
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-02       Impact factor: 8.829

View more
  6 in total

Review 1.  Complications associated with intrathecal drug delivery systems.

Authors:  E M Delhaas; F J P M Huygen
Journal:  BJA Educ       Date:  2019-12-12

2.  Dexmedetomidine for acute clonidine withdrawal following intrathecal pump removal: A drug beginning to find its expanding niche.

Authors:  Emma Bowcock; Idunn Morris; Andrew Lane
Journal:  J Intensive Care Soc       Date:  2016-07-25

Review 3.  Sympathomimetic Toxidromes and Other Pharmacological Causes of Acute Hypertension.

Authors:  Andrew King; Mirjana Dimovska; Luke Bisoski
Journal:  Curr Hypertens Rep       Date:  2018-02-24       Impact factor: 5.369

Review 4.  Caring for patients with pain during the COVID-19 pandemic: consensus recommendations from an international expert panel.

Authors:  H Shanthanna; N H Strand; D A Provenzano; C A Lobo; S Eldabe; A Bhatia; J Wegener; K Curtis; S P Cohen; S Narouze
Journal:  Anaesthesia       Date:  2020-04-26       Impact factor: 6.955

5.  Hypertensive Crisis in a Pediatric Patient Experiencing Clonidine Withdrawal.

Authors:  Can Cao; Matthew L Lorenz; Phillip Sojka; Allison W Brindle; Lisa Swartz Topor
Journal:  Case Rep Pediatr       Date:  2022-03-22

6.  Managing Intrathecal Drug Delivery Devices in a Global Pandemic.

Authors:  Philip Kim; Timothy Deer
Journal:  Neuromodulation       Date:  2020-05-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.